STARPHARMA HOLDINGS LIMITED - Announcements

18.2%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	$3.7M R&D Tax Incentive Received	PRICE SENSITIVE	28/08/25	123.28KB	Share
SPL	2025 Appendix 4G and Corporate Governance Statement		26/08/25	2.81MB	Share
SPL	FY25 Key Financial Results and Annual Report	PRICE SENSITIVE	26/08/25	595.7KB	Share
SPL	2025 Annual Report		26/08/25	3.6MB	Share
SPL	2025 Appendix 4E Preliminary Financial Report	PRICE SENSITIVE	26/08/25	157.44KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	698.06KB	Share
SPL	Notification of cessation of securities - SPL		08/07/25	12.8KB	Share
SPL	Change in substantial holding		04/06/25	536.73KB	Share
SPL	Change in substantial holding		03/06/25	145.34KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	686.07KB	Share
SPL	Notification of cessation of securities - SPL		04/04/25	12.8KB	Share
SPL	Application for quotation of securities - SPL		04/04/25	15.6KB	Share
SPL	Becoming a substantial holder		17/03/25	146.03KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/25	2.38MB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/01/25	271.62KB	Share
SPL	DEP Presentation at Targeted Radio Therapies Conference		16/01/25	2.43MB	Share
SPL	SPL receives positive FDA feedback on DEP SN38 for PROC	PRICE SENSITIVE	19/12/24	166.7KB	Share
SPL	Change of Director's Interest Notice - Ms Cheryl Maley		12/12/24	291.3KB	Share
SPL	Notification regarding unquoted securities - SPL		12/12/24	16.43KB	Share
SPL	DEP Presentation at Radiopharmaceuticals Summit		04/12/24	1.74MB	Share
SPL	Results of 2024 Reconvened Annual General Meeting		29/11/24	137.71KB	Share
SPL	AGM Notice of Reconvened Meeting		27/11/24	114.13KB	Share
SPL	Results of 2024 Annual General Meeting		26/11/24	143.74KB	Share
SPL	AGM Chair's address and CEO's presentation	PRICE SENSITIVE	26/11/24	2.35MB	Share
SPL	DEP SN38 Results Showcased at GI Cancer Conference		21/11/24	1.62MB	Share
SPL	Bell Potter Healthcare Conference Presentation		18/11/24	1.7MB	Share
SPL	Change of Director's Interest Notice		06/11/24	273.09KB	Share
SPL	Notification regarding unquoted securities - SPL		01/11/24	16.4KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	617.17KB	Share
SPL	Australian Microcap Conference Presentation		29/10/24	2.36MB	Share
SPL	Notice of Annual General Meeting/Proxy Form		28/10/24	1.53MB	Share
SPL	Application for quotation of securities - SPL		25/10/24	15.61KB	Share
SPL	Change of Director's Interest Notice - R Thomas		24/10/24	273.05KB	Share
SPL	SPL7013 Nasal Spray Australia Update	PRICE SENSITIVE	18/10/24	158.47KB	Share
SPL	Date of Annual General Meeting 2024		03/10/24	134.2KB	Share
SPL	Notification of cessation of securities - SPL		03/10/24	12.86KB	Share
SPL	Change of Director's Interest Notice - Dr Russell Basser		16/09/24	280.66KB	Share
SPL	Starpharma Receives $5.5M R&D Tax Incentive Refund	PRICE SENSITIVE	12/09/24	129.24KB	Share
SPL	Ceasing to be a substantial holder		09/09/24	179.65KB	Share
SPL	Change in Director's Interest Notice - David McIntyre		02/09/24	158.03KB	Share
SPL	Change in Director's Interest Notice - R Thomas		02/09/24	158.78KB	Share
SPL	Application for quotation of securities - SPL		28/08/24	15.61KB	Share
SPL	Change in substantial holding		27/08/24	192.79KB	Share
SPL	Appendix 4G and Corporate Governance Statement		22/08/24	2.91MB	Share
SPL	Annual Report to shareholders	PRICE SENSITIVE	22/08/24	14.97MB	Share
SPL	Change in substantial holding		16/08/24	123.85KB	Share
SPL	Change in substantial holding		02/08/24	172.11KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/24	628.88KB	Share
SPL	Change in substantial holding		02/07/24	152.24KB	Share
SPL	Application for quotation of securities - SPL		02/07/24	20.07KB	Share
SPL	Change in Director's Interest Notice - Jeff Davies		01/07/24	173.23KB	Share
SPL	Change in substantial holding		28/06/24	107.67KB	Share
SPL	Change in Director's Interest Notice - L Cheng		27/06/24	180.69KB	Share
SPL	Change in Director's Interest Notice - R Thomas		27/06/24	210KB	Share
SPL	Change in substantial holding		25/06/24	153.5KB	Share
SPL	Change in Director's Interest Notice - R Thomas		21/06/24	196.1KB	Share
SPL	DEP presentation at SNMMI radiopharmaceuticals conference		11/06/24	815.6KB	Share
SPL	Notification regarding unquoted securities - SPL		11/06/24	16.54KB	Share
SPL	DEP irinotecan presentation at ASCO 2024 Annual Meeting		04/06/24	972.45KB	Share
SPL	DEP cabazitaxel presentation at ASCO 2024 Annual Meeting		03/06/24	1.02MB	Share
SPL	Change in Director's Interest Notice - Cheryl Maley		30/05/24	167.9KB	Share
SPL	Change in Director's Interest Notice - R Thomas		30/05/24	183.39KB	Share
SPL	Positive final DEP irinotecan Phase 2 clinical trial results	PRICE SENSITIVE	27/05/24	231.8KB	Share
SPL	Starpharma Business Update	PRICE SENSITIVE	22/05/24	1.8MB	Share
SPL	Investor Webinar Notification - SPL Business Update		20/05/24	141.2KB	Share
SPL	Change in substantial holding		16/05/24	153.16KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	341.27KB	Share
SPL	Change in Director's Interest Notice - R Thomas		17/04/24	153.92KB	Share
SPL	Change in Director's Interest Notice - R Basser		16/04/24	145.3KB	Share
SPL	Change in Director's Interest Notice - R Thomas		15/04/24	144.02KB	Share
SPL	Investor Webinar Notification SPL Medicxi Partnership		08/04/24	145.32KB	Share
SPL	Starpharma and Medicxi Partnership Petalion Therapeutics	PRICE SENSITIVE	08/04/24	190.59KB	Share
SPL	S&P DJI Announces March 2024 Quarterly Rebalance	PRICE SENSITIVE	01/03/24	120.24KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/24	1.33MB	Share
SPL	VivaGel BV US FDA Appeal Outcome	PRICE SENSITIVE	19/02/24	209.89KB	Share
SPL	Application for quotation of securities - SPL		06/02/24	17.05KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	344.69KB	Share
SPL	Viraleze shows antiviral efficacy in COVID-19 patients	PRICE SENSITIVE	29/01/24	302KB	Share
SPL	VivaGel BV sales and distribution agreement MENA region	PRICE SENSITIVE	22/01/24	238.74KB	Share
SPL	DEP cabazitaxel data presentation at ASCO GI cancer meeting		19/01/24	1.61MB	Share
SPL	Notification of cessation of securities - SPL		12/01/24	21.61KB	Share
SPL	Final Director's Interest Notice - J Fairley		12/01/24	230KB	Share
SPL	Appendix 3X - Cheryl Maley		12/01/24	232.31KB	Share
SPL	Notification regarding unquoted securities - SPL		12/01/24	27.46KB	Share
SPL	Application for quotation of securities - SPL		21/12/23	26.21KB	Share
SPL	Positive DEP docetaxel Phase 2 results	PRICE SENSITIVE	19/12/23	303.21KB	Share
SPL	Change in Director's Interest Notice - J Fairley		08/12/23	162.64KB	Share
SPL	Notification regarding unquoted securities - SPL		08/12/23	26.7KB	Share
SPL	Starpharma to present DEP at Radiopharmaceuticals Summit		06/12/23	3.64MB	Share
SPL	AGM Results		29/11/23	160.38KB	Share
SPL	AGM Chairman's address and CEO presentation	PRICE SENSITIVE	29/11/23	7.75MB	Share
SPL	Application for quotation of securities - SPL		15/11/23	26.31KB	Share
SPL	Notice of Annual General Meeting 2023 - Clarification		15/11/23	199.29KB	Share
SPL	Starpharma Presents at Bell Potter Conference		14/11/23	2.63MB	Share
SPL	Application for quotation of securities - SPL		10/11/23	26.21KB	Share
SPL	Starpharma announces new CEO, Ms Cheryl Maley	PRICE SENSITIVE	10/11/23	238.8KB	Share
SPL	Notification regarding unquoted securities - SPL		06/11/23	26.34KB	Share
SPL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	722.62KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		27/10/23	14.21MB	Share
SPL	SPL to present DEP radiotheranostics at Wilsons Conference		26/10/23	2.04MB	Share

SPL $3.7M R&D Tax Incentive Received
28/08/25	PRICE SENSITIVE	123.28KB	Share
SPL 2025 Appendix 4G and Corporate Governance Statement
26/08/25		2.81MB	Share
SPL FY25 Key Financial Results and Annual Report
26/08/25	PRICE SENSITIVE	595.7KB	Share
SPL 2025 Annual Report
26/08/25		3.6MB	Share
SPL 2025 Appendix 4E Preliminary Financial Report
26/08/25	PRICE SENSITIVE	157.44KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	698.06KB	Share
SPL Notification of cessation of securities - SPL
08/07/25		12.8KB	Share
SPL Change in substantial holding
04/06/25		536.73KB	Share
SPL Change in substantial holding
03/06/25		145.34KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	686.07KB	Share
SPL Notification of cessation of securities - SPL
04/04/25		12.8KB	Share
SPL Application for quotation of securities - SPL
04/04/25		15.6KB	Share
SPL Becoming a substantial holder
17/03/25		146.03KB	Share
SPL Half Yearly Report and Accounts
26/02/25	PRICE SENSITIVE	2.38MB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
29/01/25	PRICE SENSITIVE	271.62KB	Share
SPL DEP Presentation at Targeted Radio Therapies Conference
16/01/25		2.43MB	Share
SPL SPL receives positive FDA feedback on DEP SN38 for PROC
19/12/24	PRICE SENSITIVE	166.7KB	Share
SPL Change of Director's Interest Notice - Ms Cheryl Maley
12/12/24		291.3KB	Share
SPL Notification regarding unquoted securities - SPL
12/12/24		16.43KB	Share
SPL DEP Presentation at Radiopharmaceuticals Summit
04/12/24		1.74MB	Share
SPL Results of 2024 Reconvened Annual General Meeting
29/11/24		137.71KB	Share
SPL AGM Notice of Reconvened Meeting
27/11/24		114.13KB	Share
SPL Results of 2024 Annual General Meeting
26/11/24		143.74KB	Share
SPL AGM Chair's address and CEO's presentation
26/11/24	PRICE SENSITIVE	2.35MB	Share
SPL DEP SN38 Results Showcased at GI Cancer Conference
21/11/24		1.62MB	Share
SPL Bell Potter Healthcare Conference Presentation
18/11/24		1.7MB	Share
SPL Change of Director's Interest Notice
06/11/24		273.09KB	Share
SPL Notification regarding unquoted securities - SPL
01/11/24		16.4KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	617.17KB	Share
SPL Australian Microcap Conference Presentation
29/10/24		2.36MB	Share
SPL Notice of Annual General Meeting/Proxy Form
28/10/24		1.53MB	Share
SPL Application for quotation of securities - SPL
25/10/24		15.61KB	Share
SPL Change of Director's Interest Notice - R Thomas
24/10/24		273.05KB	Share
SPL SPL7013 Nasal Spray Australia Update
18/10/24	PRICE SENSITIVE	158.47KB	Share
SPL Date of Annual General Meeting 2024
03/10/24		134.2KB	Share
SPL Notification of cessation of securities - SPL
03/10/24		12.86KB	Share
SPL Change of Director's Interest Notice - Dr Russell Basser
16/09/24		280.66KB	Share
SPL Starpharma Receives $5.5M R&D Tax Incentive Refund
12/09/24	PRICE SENSITIVE	129.24KB	Share
SPL Ceasing to be a substantial holder
09/09/24		179.65KB	Share
SPL Change in Director's Interest Notice - David McIntyre
02/09/24		158.03KB	Share
SPL Change in Director's Interest Notice - R Thomas
02/09/24		158.78KB	Share
SPL Application for quotation of securities - SPL
28/08/24		15.61KB	Share
SPL Change in substantial holding
27/08/24		192.79KB	Share
SPL Appendix 4G and Corporate Governance Statement
22/08/24		2.91MB	Share
SPL Annual Report to shareholders
22/08/24	PRICE SENSITIVE	14.97MB	Share
SPL Change in substantial holding
16/08/24		123.85KB	Share
SPL Change in substantial holding
02/08/24		172.11KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
30/07/24	PRICE SENSITIVE	628.88KB	Share
SPL Change in substantial holding
02/07/24		152.24KB	Share
SPL Application for quotation of securities - SPL
02/07/24		20.07KB	Share
SPL Change in Director's Interest Notice - Jeff Davies
01/07/24		173.23KB	Share
SPL Change in substantial holding
28/06/24		107.67KB	Share
SPL Change in Director's Interest Notice - L Cheng
27/06/24		180.69KB	Share
SPL Change in Director's Interest Notice - R Thomas
27/06/24		210KB	Share
SPL Change in substantial holding
25/06/24		153.5KB	Share
SPL Change in Director's Interest Notice - R Thomas
21/06/24		196.1KB	Share
SPL DEP presentation at SNMMI radiopharmaceuticals conference
11/06/24		815.6KB	Share
SPL Notification regarding unquoted securities - SPL
11/06/24		16.54KB	Share
SPL DEP irinotecan presentation at ASCO 2024 Annual Meeting
04/06/24		972.45KB	Share
SPL DEP cabazitaxel presentation at ASCO 2024 Annual Meeting
03/06/24		1.02MB	Share
SPL Change in Director's Interest Notice - Cheryl Maley
30/05/24		167.9KB	Share
SPL Change in Director's Interest Notice - R Thomas
30/05/24		183.39KB	Share
SPL Positive final DEP irinotecan Phase 2 clinical trial results
27/05/24	PRICE SENSITIVE	231.8KB	Share
SPL Starpharma Business Update
22/05/24	PRICE SENSITIVE	1.8MB	Share
SPL Investor Webinar Notification - SPL Business Update
20/05/24		141.2KB	Share
SPL Change in substantial holding
16/05/24		153.16KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	341.27KB	Share
SPL Change in Director's Interest Notice - R Thomas
17/04/24		153.92KB	Share
SPL Change in Director's Interest Notice - R Basser
16/04/24		145.3KB	Share
SPL Change in Director's Interest Notice - R Thomas
15/04/24		144.02KB	Share
SPL Investor Webinar Notification SPL Medicxi Partnership
08/04/24		145.32KB	Share
SPL Starpharma and Medicxi Partnership Petalion Therapeutics
08/04/24	PRICE SENSITIVE	190.59KB	Share
SPL S&P DJI Announces March 2024 Quarterly Rebalance
01/03/24	PRICE SENSITIVE	120.24KB	Share
SPL Half Yearly Report and Accounts
28/02/24	PRICE SENSITIVE	1.33MB	Share
SPL VivaGel BV US FDA Appeal Outcome
19/02/24	PRICE SENSITIVE	209.89KB	Share
SPL Application for quotation of securities - SPL
06/02/24		17.05KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	344.69KB	Share
SPL Viraleze shows antiviral efficacy in COVID-19 patients
29/01/24	PRICE SENSITIVE	302KB	Share
SPL VivaGel BV sales and distribution agreement MENA region
22/01/24	PRICE SENSITIVE	238.74KB	Share
SPL DEP cabazitaxel data presentation at ASCO GI cancer meeting
19/01/24		1.61MB	Share
SPL Notification of cessation of securities - SPL
12/01/24		21.61KB	Share
SPL Final Director's Interest Notice - J Fairley
12/01/24		230KB	Share
SPL Appendix 3X - Cheryl Maley
12/01/24		232.31KB	Share
SPL Notification regarding unquoted securities - SPL
12/01/24		27.46KB	Share
SPL Application for quotation of securities - SPL
21/12/23		26.21KB	Share
SPL Positive DEP docetaxel Phase 2 results
19/12/23	PRICE SENSITIVE	303.21KB	Share
SPL Change in Director's Interest Notice - J Fairley
08/12/23		162.64KB	Share
SPL Notification regarding unquoted securities - SPL
08/12/23		26.7KB	Share
SPL Starpharma to present DEP at Radiopharmaceuticals Summit
06/12/23		3.64MB	Share
SPL AGM Results
29/11/23		160.38KB	Share
SPL AGM Chairman's address and CEO presentation
29/11/23	PRICE SENSITIVE	7.75MB	Share
SPL Application for quotation of securities - SPL
15/11/23		26.31KB	Share
SPL Notice of Annual General Meeting 2023 - Clarification
15/11/23		199.29KB	Share
SPL Starpharma Presents at Bell Potter Conference
14/11/23		2.63MB	Share
SPL Application for quotation of securities - SPL
10/11/23		26.21KB	Share
SPL Starpharma announces new CEO, Ms Cheryl Maley
10/11/23	PRICE SENSITIVE	238.8KB	Share
SPL Notification regarding unquoted securities - SPL
06/11/23		26.34KB	Share
SPL Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	722.62KB	Share
SPL Notice of Annual General Meeting/Proxy Form
27/10/23		14.21MB	Share
SPL SPL to present DEP radiotheranostics at Wilsons Conference
26/10/23		2.04MB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.020(18.2%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
11.5¢	13.5¢	11.0¢	$25.52K	200.4K

Buyers (Bids)

No.	Vol.	Price($)
1	617923	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	108845	7

View Market Depth

No.	Vol.	Price($)
1	617923	0.130
2	56308	0.125
1	50000	0.120
1	43350	0.115
3	13597	0.110

Price($)	Vol.	No.
0.135	102840	6
0.140	161341	4
0.145	112695	8
0.150	175000	3
0.155	50000	1

Last trade - 16.10pm 04/09/2025 (20 minute delay)


Last 13.5¢		Change 0.020 ( 20.0 %)
Open	High	Low	Volume
11.3¢	13.5¢	11.3¢	186899
Last updated 16.00pm 04/09/2025 ?

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories